Soleno Therapeutics (SLNO) Income towards Parent Company (2013 - 2026)

Soleno Therapeutics (SLNO) has 13 years of Income towards Parent Company data on file, last reported at $31.4 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 171.68% year-over-year to $31.4 million in Q1 2026; TTM through Mar 2026 was -$185.2 million, a 49.29% increase from a year earlier, with the FY2025 full-year figure at -$53.5 million, up 79.34% from the prior year.
• Income towards Parent Company for Q1 2026 stood at $31.4 million, down from $43.5 million in the prior quarter.
• Over the last five years, Income towards Parent Company for SLNO reached as high as $43.5 million in Q4 2025 and fell as low as -$173.9 million in Q2 2025.
• Historically, Income towards Parent Company has averaged -$48.2 million across 5 years, with a median of -$43.8 million in 2025.
• Across the five-year window, Income towards Parent Company slumped 1080.64% in 2024 and soared 178.03% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$62.6 million in 2022, then surged by 81.63% to -$11.5 million in 2023, then tumbled by 384.56% to -$55.7 million in 2024, then surged by 178.03% to $43.5 million in 2025, then fell by 27.85% to $31.4 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were $31.4 million in Q1 2026, $43.5 million in Q4 2025, and -$86.2 million in Q3 2025.